发明名称 Controlled- or delayed-release forms of topiramate
摘要 The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutical unit dosage forms containing the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compositions comprising them. The invention also encompasses methods of treating or preventing a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.
申请公布号 US6699840(B2) 申请公布日期 2004.03.02
申请号 US20020295995 申请日期 2002.11.18
申请人 TRANSFORM PHARMACEUTICALS INC 发明人 ALMARSSON OERN;REMENAR JULIUS F;PETERSON MATTHEW L
分类号 C07D473/12;A61K9/00;A61K9/16;A61K31/19;A61K31/195;A61K31/4015;A61K31/4166;A61K31/522;A61K31/53;A61K31/55;A61K31/7028;A61K47/10;A61K47/32;A61P1/08;A61P1/14;A61P3/04;A61P9/12;A61P11/02;A61P15/00;A61P25/00;A61P25/04;A61P25/06;A61P25/08;A61P25/14;A61P25/16;A61P25/18;A61P25/22;A61P25/24;A61P25/28;A61P25/30;A61P25/34;A61P27/02;A61P43/00;C07H5/04;C07H5/06;C07H11/00;G01N33/15;(IPC1-7):A01N43/04;A01N43/16;A61K31/70;A61K31/35 主分类号 C07D473/12
代理机构 代理人
主权项
地址